GT200900023BA - Formas de dosificación farmacéutica - Google Patents

Formas de dosificación farmacéutica

Info

Publication number
GT200900023BA
GT200900023BA GT200900023BA GT200900023A GT200900023BA GT 200900023B A GT200900023B A GT 200900023BA GT 200900023B A GT200900023B A GT 200900023BA GT 200900023 A GT200900023 A GT 200900023A GT 200900023B A GT200900023B A GT 200900023BA
Authority
GT
Guatemala
Prior art keywords
pharmaceutical dosage
dosage forms
forms
treatment
methods
Prior art date
Application number
GT200900023BA
Other languages
English (en)
Spanish (es)
Inventor
Richard Owen Mannion
Edward Patrick O'donnell
William Henry Mckenna
Haiyong Hugo Huang
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38754532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200900023B(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of GT200900023BA publication Critical patent/GT200900023BA/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B7/00—Mixing; Kneading
    • B29B7/02—Mixing; Kneading non-continuous, with mechanical mixing or kneading devices, i.e. batch type
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B7/00—Mixing; Kneading
    • B29B7/80—Component parts, details or accessories; Auxiliary operations
    • B29B7/88—Adding charges, i.e. additives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C35/04—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam
    • B29C35/045—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/16—Cooling
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C37/00—Component parts, details, accessories or auxiliary operations, not covered by group B29C33/00 or B29C35/00
    • B29C37/0025—Applying surface layers, e.g. coatings, decorative layers, printed layers, to articles during shaping, e.g. in-mould printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/02—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor of articles of definite length, i.e. discrete articles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/32—Component parts, details or accessories; Auxiliary operations
    • B29C43/52—Heating or cooling
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C71/00—After-treatment of articles without altering their shape; Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C71/00—After-treatment of articles without altering their shape; Apparatus therefor
    • B29C71/009—After-treatment of articles without altering their shape; Apparatus therefor using gases without chemical reaction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C35/04—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam
    • B29C35/045—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames
    • B29C2035/046—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames dried air
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/16—Cooling
    • B29C2035/1658—Cooling using gas
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2071/00—Use of polyethers, e.g. PEEK, i.e. polyether-etherketone or PEK, i.e. polyetherketone or derivatives thereof, as moulding material
    • B29K2071/02—Polyalkylene oxides, e.g. PEO, i.e. polyethylene oxide, or derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/25—Solid
    • B29K2105/251—Particles, powder or granules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037—Other properties
    • B29K2995/0088—Molecular weight
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mechanical Engineering (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Thermal Sciences (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plasma & Fusion (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GT200900023BA 2006-08-25 2009-02-05 Formas de dosificación farmacéutica GT200900023BA (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84024406P 2006-08-25 2006-08-25

Publications (1)

Publication Number Publication Date
GT200900023BA true GT200900023BA (es) 2018-09-28

Family

ID=38754532

Family Applications (2)

Application Number Title Priority Date Filing Date
GT200900023A GT200900023A (es) 2006-08-25 2009-02-05 Formas farmacéuticas de dosificación oral que contienen un analgésico opioide.
GT200900023BA GT200900023BA (es) 2006-08-25 2009-02-05 Formas de dosificación farmacéutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GT200900023A GT200900023A (es) 2006-08-25 2009-02-05 Formas farmacéuticas de dosificación oral que contienen un analgésico opioide.

Country Status (42)

Country Link
US (64) US8894987B2 (el)
EP (11) EP2082742B1 (el)
JP (8) JP5069300B2 (el)
KR (8) KR101649838B1 (el)
CN (9) CN103861111B (el)
AP (1) AP2009004770A0 (el)
AR (4) AR062511A1 (el)
AT (5) ATE444070T1 (el)
AU (1) AU2007287341B2 (el)
BR (2) BR122016004010B8 (el)
CA (2) CA2707204C (el)
CL (3) CL2007002485A1 (el)
CO (1) CO6160317A2 (el)
CR (2) CR10691A (el)
CY (7) CY1110573T1 (el)
DE (5) DE602007010963D1 (el)
DK (11) DK2399580T3 (el)
DO (2) DOP2009000026A (el)
EA (3) EA023807B1 (el)
ES (11) ES2334466T3 (el)
GT (2) GT200900023A (el)
HK (12) HK1118225A1 (el)
HR (11) HRP20090688T1 (el)
IL (10) IL197214A (el)
IN (1) IN2015DN01813A (el)
JO (2) JO2858B1 (el)
MA (1) MA30766B1 (el)
ME (7) ME01064B (el)
MX (2) MX360849B (el)
MY (3) MY153092A (el)
NZ (3) NZ574447A (el)
PE (5) PE20150340A1 (el)
PL (11) PL2311459T3 (el)
PT (11) PT2311459E (el)
RS (11) RS51664B (el)
SA (1) SA07280459B1 (el)
SI (11) SI2384754T1 (el)
TN (1) TN2009000059A1 (el)
TW (1) TWI341213B (el)
UA (2) UA104745C2 (el)
WO (1) WO2008023261A1 (el)
ZA (1) ZA200900755B (el)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CA2801155A1 (en) 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) * 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
HUE037643T2 (hu) 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Visszaélésre nem alkalmas gyógyszerkészítmények
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
PL2415484T3 (pl) 2004-09-17 2014-11-28 Durect Corp Kompozycja znieczulająca miejscowo o przedłużonym uwalnianiu zawierająca SAIB
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20090274759A1 (en) * 2005-06-03 2009-11-05 Egalet A/S Solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP2484347A1 (en) 2006-11-03 2012-08-08 Durect Corporation Transdermal delivery systems comprising bupivacaine
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20080318994A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
ES2692437T3 (es) 2007-08-13 2018-12-03 Abuse Deterrent Pharmaceutical Llc Fármacos resistentes al abuso, método de uso y método de preparación
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
NZ586792A (en) * 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CA2720108C (en) * 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PT2273983T (pt) 2008-05-09 2016-10-28 Gruenenthal Gmbh Processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob utilização de uma etapa de congelamento por atomização
WO2010032128A1 (en) * 2008-09-18 2010-03-25 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
MX2011006173A (es) 2008-12-12 2011-09-01 Paladin Labs Inc Formulaciones de drogas narcoticas con disminuido potencial de abuso.
WO2010088911A1 (en) 2009-02-06 2010-08-12 Egalet A/S Pharmaceutical compositions resistant to abuse
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
US20100278915A1 (en) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
EP2424534A2 (en) * 2009-05-01 2012-03-07 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
SI2456424T1 (sl) 2009-07-22 2013-10-30 Gruenenthal Gmbh Oksidacijsko stabilizirana odmerna oblika, varna pred zlorabo
AU2010275753B2 (en) 2009-07-22 2014-08-21 Grünenthal GmbH Hot-melt extruded controlled release dosage form
RU2012112552A (ru) * 2009-08-31 2013-10-10 Дипомед, Инк. Удерживаемые в желудке фармацевтические композиции для немедленного и продленного высвобождения ацетаминофена
EP3064064A1 (en) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2531176B1 (en) * 2010-02-03 2016-09-07 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
AR083150A1 (es) 2010-05-10 2013-02-06 Euro Celtique Sa Composiciones farmaceuticas que comprenden hidromorfona y naloxona
BR112012028788A2 (pt) 2010-05-10 2016-07-19 Euro Celtique Sa fabricação de grânulos sem ativos
BR112012028656A2 (pt) 2010-05-10 2016-08-09 Euro Celtique Sa combinação de grânulos carregados ativos com ativos adicionais
HUE026619T2 (en) 2010-06-15 2016-06-28 Gruenenthal Gmbh Medical combination for treatment of pain
KR20130137627A (ko) 2010-09-02 2013-12-17 그뤼넨탈 게엠베하 음이온성 중합체를 포함하는 내변조성 투여형
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US9233076B2 (en) 2010-12-13 2016-01-12 Purdue Pharma L.P. Controlled release dosage forms
EP2826469A1 (en) * 2010-12-22 2015-01-21 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
CN104856967A (zh) * 2010-12-22 2015-08-26 普渡制药公司 包覆的抗篡改控制释放剂型
CA2822769C (en) * 2010-12-23 2016-10-04 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
CA2831218C (en) * 2011-03-25 2017-01-17 Purdue Pharma L.P. Controlled release pharmaceutical dosage forms
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
AT511581A1 (de) 2011-05-26 2012-12-15 G L Pharma Gmbh Orale retardierende formulierung
EP2736497B1 (en) 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
CA2847611A1 (en) * 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP3078370B1 (en) * 2011-09-16 2018-11-07 Purdue Pharma L.P. Tamper resistant immediate release formulations
CN103889456A (zh) * 2011-10-18 2014-06-25 普渡制药公司 丙烯酸类聚合物制剂
PE20141671A1 (es) 2011-11-17 2014-11-22 Gruenenthal Chemie Forma de dosis farmaceutica oral a prueba de manipulacion que comprende un agente antagonista y/o repelente opioide, oxido de polialquileno y un polimero anionico
WO2013077851A1 (en) * 2011-11-22 2013-05-30 Watson Pharmaceuticals, Inc. Immediate release abuse deterrent tablet
AU2012327231B2 (en) * 2011-12-09 2015-09-24 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
AU2013225106B2 (en) 2012-02-28 2017-11-02 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
EP2838516B1 (en) 2012-04-18 2018-10-17 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
ES2692944T3 (es) 2012-04-18 2018-12-05 Grünenthal GmbH Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
ES2698611T3 (es) * 2012-07-12 2019-02-05 SpecGx LLC Composiciones farmacéuticas disuasorias del abuso y de liberación prolongada
CN107595793B (zh) 2012-11-30 2020-11-13 阿库拉制药公司 活性药物成分的自调节释放
EP2953618B1 (en) 2013-02-05 2020-11-11 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
MX2015013231A (es) 2013-03-15 2016-06-07 Inspirion Delivery Technologies Llc Composiciones que disuaden el abuso y metodos de utilizacion.
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2901802C (en) 2013-03-15 2021-03-02 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
WO2014191397A1 (en) * 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
BR112015029616A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem resistente à adulteração com perfil de liberação bimodal
MX368846B (es) 2013-07-12 2019-10-18 Gruenenthal Gmbh Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CA2931553C (en) 2013-11-26 2022-01-18 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10632113B2 (en) 2014-02-05 2020-04-28 Kashiv Biosciences, Llc Abuse-resistant drug formulations with built-in overdose protection
EP3122337A4 (en) 2014-03-26 2017-11-08 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release coated reservoir solid dosage form
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
BR112016030648B1 (pt) 2014-07-03 2023-10-03 SpecGx LLC Composições farmacêticas de liberação imediata de impedimento de abuso compreendendo polissacarídeos não celulósicos
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
JP5888387B1 (ja) * 2014-10-22 2016-03-22 ミツミ電機株式会社 電池保護回路及び電池保護装置、並びに電池パック
JP2018515455A (ja) 2015-04-24 2018-06-14 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 粒子から２種の薬物の急速放出をもたらすタンパレジスタントな固定用量組合せ
AU2016251302A1 (en) 2015-04-24 2017-11-23 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix
JP2018513872A (ja) 2015-04-24 2018-05-31 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 異なる粒子から２種の薬物の急速放出をもたらすタンパレジスタントな固定用量組合せ
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
US20190054031A1 (en) * 2015-09-30 2019-02-21 Kashiv Pharma Llc Overdose protection and abuse deterrent immediate release drug formulation
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US20180303757A1 (en) * 2015-10-23 2018-10-25 Kashiv Pharma Llc Enhanced abuse-deterrent formulations of oxycodone
JP2019504072A (ja) * 2016-02-08 2019-02-14 スペックジーエックス エルエルシー 徐放性及び濫用抑止特性を有するグルコマンナン含有医薬組成物
JP6323846B2 (ja) * 2016-04-07 2018-05-16 塩野義製薬株式会社 オピオイドを含有する乱用防止製剤
US20170296476A1 (en) 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
WO2018024709A1 (en) 2016-08-01 2018-02-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polysaccharide
BR112019002789A2 (pt) 2016-08-12 2019-05-21 Grünenthal GmbH formulação de efedrina resistente à adulteração e seus derivados
DE202016105585U1 (de) * 2016-10-06 2017-01-23 L.B. Bohle Maschinen + Verfahren Gmbh Anlage zur Herstellung pharmazeutischer Tabletten
USD857156S1 (en) * 2016-11-02 2019-08-20 Innovative Water Care, Llc Chemical tablet for aquatic systems
EP3554548A4 (en) 2016-12-19 2020-08-19 The Regents of The University of California NON-CRUSHABLE PILL FORMULATIONS
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019003062A1 (en) * 2017-06-29 2019-01-03 Zenvision Pharma Llp INVIOLABLE GALENIC FORM COMPRISING A PHARMACEUTICALLY ACTIVE AGENT
US10376471B2 (en) * 2017-07-10 2019-08-13 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
BR112020006995A2 (pt) 2017-10-13 2020-10-06 Grünenthal GmbH formas de dosagem de dissuasão de abuso de liberação modificada
EP3697393A4 (en) 2017-10-20 2021-10-13 Purdue Pharma LP PHARMACEUTICAL DOSAGE FORMS
JP7377202B2 (ja) * 2017-12-20 2023-11-09 パーデュー、ファーマ、リミテッド、パートナーシップ 乱用抑止硫酸モルヒネ剤形
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
TW202002957A (zh) 2018-02-09 2020-01-16 德商歌林達有限公司 包含轉化抑制劑之麻黃素及其衍生物之抗損壞調配物
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
JP7499232B2 (ja) * 2018-09-06 2024-06-13 ファハホーホシューレ ノルドヴェストシュヴァイツ 薬剤放出制御剤形
MX2021002459A (es) 2018-09-25 2021-04-29 SpecGx LLC Formas de dosificacion en capsula disuasorias del abuso de liberacion inmediata.
CN112702995A (zh) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070547A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US20210378989A1 (en) 2018-10-11 2021-12-09 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
WO2020079699A1 (en) * 2018-10-16 2020-04-23 M.O Advanced Technologies (Moat) Ltd Apparatus and method for prediction of tablet defects propensity
CN111251521B (zh) * 2018-12-03 2022-07-22 沈欣 液态珠丸的制造方法
EP3698776A1 (en) 2019-02-19 2020-08-26 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
CN110946086B (zh) * 2019-12-04 2023-05-12 北京猫猫狗狗科技有限公司 一种下料装置以及下料控制方法
WO2021137148A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
USD943706S1 (en) * 2020-06-10 2022-02-15 Emily Florence Johns Shower steamer
CN114659554B (zh) * 2022-03-01 2023-04-25 安徽农业大学 一种生物质颗粒机故障诊断方法

Family Cites Families (298)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1485673A (en) * 1924-03-04 Ministrator
US1479293A (en) 1924-01-01 Hiabtor fbettlid
US1468805A (en) 1923-09-25 Htabtin ereund
US636438A (en) 1899-02-08 1899-11-07 Charles H Lovejoy Molder's chaplet.
US2654756A (en) 1949-10-20 1953-10-06 Mallinckrodt Chemical Works Process of preparing codeinone, dihydrocodeinone, and dihydromorphinone
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US3096248A (en) 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3097144A (en) 1960-10-14 1963-07-09 Upjohn Co Heat-cured, polymeric, medicinal dosage film coatings containing a polyvinylpyrrolidone copolymer, polyethenoid acid, and polyethylene glycol
US3806603A (en) * 1969-10-13 1974-04-23 W Gaunt Pharmaceutical carriers of plasticized dried milled particles of hydrated cooked rice endosperm
US3885027A (en) 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3966747A (en) * 1972-10-26 1976-06-29 Bristol-Myers Company 9-Hydroxy-6,7-benzomorphans
US3888027A (en) 1973-07-30 1975-06-10 Kennametal Inc Arrangement for enhancing blade life
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3941865A (en) * 1973-12-10 1976-03-02 Union Carbide Corporation Extrusion of ethylene oxide resins
DE2530563C2 (de) * 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
GB1598458A (en) 1977-04-01 1981-09-23 Hoechst Uk Ltd Tableting of microcapsules
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4211681A (en) 1978-08-16 1980-07-08 Union Carbide Corporation Poly(ethylene oxide) compositions
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3002664C2 (de) 1980-01-25 1989-05-18 Titmus Eurocon Kontaktlinsen Gmbh & Co Kg, 8750 Aschaffenburg Weiche Kontaktlinse
IL70071A (en) 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4501828A (en) * 1983-01-20 1985-02-26 General Technology Applications,Inc. Dissolving water soluble polymers
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
FR2557459B1 (fr) 1984-01-02 1986-05-30 Lhd Lab Hygiene Dietetique Matrice inerte a base de polycaprolactone pour administration orale d'un medicament, et procede de preparation de la forme galenique comprenant cette matrice
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
AU592065B2 (en) 1984-10-09 1990-01-04 Dow Chemical Company, The Sustained release dosage form based on highly plasticized cellulose ether gels
GB8507779D0 (en) 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
US4616644A (en) 1985-06-14 1986-10-14 Johnson & Johnson Products, Inc. Hemostatic adhesive bandage
DE3673789D1 (de) 1985-06-24 1990-10-04 Ici Australia Ltd Einnehmbare kapseln.
US4619988A (en) 1985-06-26 1986-10-28 Allied Corporation High strength and high tensile modulus fibers or poly(ethylene oxide)
DE3665262D1 (en) 1985-06-28 1989-10-05 Carrington Lab Inc Processes for preparation of aloe products, products produced thereby and compositions thereof
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
DE3689650T2 (de) 1985-12-17 1994-05-26 United States Surgical Corp Bioresorbierbare Polymere von hohem Molekulargewicht und Implantate davon.
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
AU622610B2 (en) 1986-11-10 1992-04-16 Biopure Corporation Extra pure semi-synthetic blood substitute
DE3643789A1 (de) 1986-12-20 1988-06-30 Bayer Ag Thermoplastisch verarbeitbare, im wesentlichen lineare poly-(alpha)-aryl-olefin/polyurethan-blockcopolymere, verfahren zu deren herstellung und deren verwendung
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US4960814A (en) 1988-06-13 1990-10-02 Eastman Kodak Company Water-dispersible polymeric compositions
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5004601A (en) 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5139790A (en) * 1988-10-14 1992-08-18 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5330766A (en) 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5051222A (en) 1989-09-01 1991-09-24 Air Products And Chemicals, Inc. Method for making extrudable polyvinyl alcohol compositions
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
FR2664851B1 (fr) * 1990-07-20 1992-10-16 Oreal Procede de compactage d'un melange pulverulent permettant d'obtenir un produit compact absorbant ou partiellement delitable et produit obtenu par ce procede.
SE9003904D0 (sv) 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
AU2670292A (en) 1991-10-04 1993-05-03 Olin Corporation Fungicide tablet
EP0612253A4 (en) * 1991-11-12 1995-08-09 Nepera Inc ANKLEBENOK HYDROGELS WITH EXTENDED LIFE AND METHOD FOR THEIR PRODUCTION.
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
ATE140620T1 (de) 1991-12-05 1996-08-15 Mallinckrodt Veterinary Inc Glasartige kohlenhydratenmatrize zur verabreichung von heilmitteln mit verzögerter wirkstoffabgabe
AU671811B2 (en) 1991-12-18 1996-09-12 Warner-Lambert Company A process for the preparation of a solid dispersion
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
EP0620728B1 (en) 1992-01-13 1997-01-08 Pfizer Inc. Preparation of tablets of increased strength
US5393528A (en) * 1992-05-07 1995-02-28 Staab; Robert J. Dissolvable device for contraception or delivery of medication
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
DK0661045T3 (da) 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
AU679937B2 (en) 1992-11-18 1997-07-17 Johnson & Johnson Consumer Products, Inc. Extrudable compositions for topical or transdermal drug delivery
FR2701152B1 (fr) 1993-02-03 1995-03-10 Digipress Sa Procédé de fabrication d'un disque maître pour la réalisation d'une matrice de pressage notamment de disques optiques, matrice de pressage obtenue par ce procédé et disque optique obtenu à partir de cette matrice de pressage.
DE4309528C2 (de) 1993-03-24 1998-05-20 Doxa Gmbh Folie oder Folienschlauch aus Casein, Verfahren zu deren Herstellung und deren Verwendung
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
HU218673B (hu) 1993-10-07 2000-10-28 Euroceltique S.A. Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
ATE212224T1 (de) 1993-11-23 2002-02-15 Euro Celtique Sa Verfahren zur herstellung einer arzneizusammensetzung mit verzögerter wirkstoffabgabe
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
WO1995022319A1 (en) 1994-02-16 1995-08-24 Abbott Laboratories Process for preparing fine particle pharmaceutical formulations
DE69505949T2 (de) 1994-02-17 1999-06-02 Pankaj Hamilton Ontario Modi Arzneimittel, impfstoffe und hormone in polylaktidbeschichteten mikropartikel
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
SK282854B6 (sk) 1994-05-06 2002-12-03 Pfizer Inc. Dávkovacia forma s riadeným uvoľňovaním obsahujúca azitromycín
AT403988B (de) 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
CA2130410C (en) 1994-08-18 2001-12-04 Albert John Kerklaan Retractable expandable jack
US6491945B1 (en) 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US5516808A (en) 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE4446470A1 (de) * 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von teilbaren Tabletten
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5695781A (en) 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6117453A (en) 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
ATE214596T1 (de) 1995-04-14 2002-04-15 Pharma Pass Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5634702A (en) 1995-09-27 1997-06-03 Fistonich; Juraj Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
DE19547766A1 (de) 1995-12-20 1997-06-26 Gruenenthal Gmbh 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-verbindungen als pharmazeutische Wirkstoffe
US5783212A (en) 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
AU2059297A (en) * 1996-03-12 1997-10-01 Alza Corporation Composition and dosage form comprising opioid antagonist
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US20020114838A1 (en) * 1996-04-05 2002-08-22 Ayer Atul D. Uniform drug delivery therapy
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
WO1997037689A2 (en) 1996-04-10 1997-10-16 Warner-Lambert Company Denaturants for sympathomimetic amine salts
US5886164A (en) * 1996-04-15 1999-03-23 Zeneca Limited DNA encoding enzymes related to ethylene biosynthesis and ripening from banana
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
GB9611328D0 (en) 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
AU3404997A (en) 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
US5955096A (en) 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
PT1014941E (pt) 1996-06-26 2009-07-08 Univ Texas Formulação farmacêutica extrudível por termofusão
US5730564A (en) 1996-07-24 1998-03-24 Illinois Tool Works Inc. Cargo load supporting air bag having inflation indicating means, and method of determining proper inflation for spaced loads
DE19630236A1 (de) 1996-07-26 1998-01-29 Wolff Walsrode Ag Biaxial gereckte, biologisch abbaubare und kompostierbare Wursthülle
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
BE1010353A5 (fr) 1996-08-14 1998-06-02 Boss Pharmaceuticals Ag Procede pour la fabrication de produits pharmaceutiques, dispositif pour un tel procede et produits pharmaceutiques ainsi obtenus.
EP0937120B1 (en) 1996-11-05 2004-09-22 NOVAMONT S.p.A. Biodegradable polymeric compositions comprising starch and a thermoplastic polymer
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
FR2761605B1 (fr) 1997-04-07 2001-02-23 Prographarm Lab Forme pharmaceutique multiparticulaire, ses particules constitutives, procede et installation pour leur fabrication
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) * 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
IL121038A0 (en) 1997-06-09 1997-11-20 Technion Res & Dev Foundation A pharmaceutical composition for lowering glucose level in blood
DE19724181A1 (de) 1997-06-09 1998-12-10 Bayer Ag Multiple-unit-retard-Zubereitungen und Verfahren zu ihrer Herstellung
AU8532798A (en) 1997-06-13 1998-12-30 Roland Bodmeier Compounds which delay the release of active substances
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
CA2270975C (en) 1997-07-02 2003-04-01 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
BR9812828A (pt) * 1997-09-26 2000-08-08 Magna Interior Sys Inc Conjunto fixador para prender e alinhar dois painéis, e, processo para instalar um painel suportado a um painel suporte
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
DE19749724A1 (de) 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
CA2310847C (en) * 1997-11-28 2007-03-13 Knoll Aktiengesellschaft Method for producing solvent-free non-crystalline biologically active substances
DE19753534A1 (de) 1997-12-03 1999-06-10 Bayer Ag Schnell kristallisierende, biologisch abbaubare Polyesteramide
GB9726365D0 (en) 1997-12-13 1998-02-11 Ciba Sc Holding Ag Compounds
CA2314896C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
EP1039908B1 (en) 1997-12-22 2004-02-25 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
TR200001942T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
DE19800698A1 (de) 1998-01-10 1999-07-15 Bayer Ag Biologisch abbaubare Polyesteramide mit blockartig aufgebauten Polyester- und Polyamid-Segmenten
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
WO1999045067A1 (fr) 1998-03-05 1999-09-10 Mitsui Chemicals, Inc. Composition a base d'acide polylactique et son film
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
DE19822979A1 (de) 1998-05-25 1999-12-02 Kalle Nalo Gmbh & Co Kg Folie mit Stärke oder Stärkederivaten und Polyesterurethanen sowie Verfahren zu ihrer Herstellung
EP0974343B1 (en) 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
US6117452A (en) 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
DE19855440A1 (de) 1998-12-01 2000-06-08 Basf Ag Verfahren zum Herstellen fester Darreichungsformen mittels Schmelzextrusion
IE981008A1 (en) 1998-12-02 2000-06-14 Fuisz Internat Ltd Microparticles Containing Water Insoluble Active Agents
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
DE19901683B4 (de) 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19940944B4 (de) * 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
CN1202815C (zh) 1999-08-31 2005-05-25 格吕伦塔尔有限公司 含有曲马朵糖精盐的持续释放给药剂型
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6491683B1 (en) 1999-09-07 2002-12-10 Alza Corporation Osmotic dosage form composed of an extruded polymer tube form
US6177567B1 (en) * 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
DE19960494A1 (de) * 1999-12-15 2001-06-21 Knoll Ag Vorrichtung und Verfahren zum Herstellen von festen wirkstoffhaltigen Formen
WO2001045644A2 (en) 1999-12-23 2001-06-28 Combe International Ltd. Dental adhesive device and method for producing same
ECSP003314A (es) 2000-01-11 2000-03-22 Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide y un - agonista
US6680070B1 (en) 2000-01-18 2004-01-20 Albemarle Corporation Particulate blends and compacted products formed therefrom, and the preparation thereof
MXPA02007686A (es) 2000-02-08 2003-03-27 Euro Celtique Sa Formulaciones orales y resistentes a intervenciones de agonistas opioides..
US6277409B1 (en) * 2000-02-11 2001-08-21 Mcneil-Ppc, Inc. Protective coating for tablet
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
DE10025948A1 (de) 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
DE10025947A1 (de) 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination enthaltend Montirelin und eine Verbindung mit opioider Wirksamkeit
WO2001092188A1 (fr) 2000-05-29 2001-12-06 Shionogi & Co., Ltd. Procede de marquage au tritium
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
DE10036400A1 (de) 2000-07-26 2002-06-06 Mitsubishi Polyester Film Gmbh Weiße, biaxial orientierte Polyesterfolie
WO2002026928A1 (en) 2000-09-28 2002-04-04 The Dow Chemical Company Polymer composite structures useful for controlled release systems
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20020187192A1 (en) 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
WO2002092060A1 (en) * 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
JP2005515960A (ja) * 2001-05-11 2005-06-02 エンドー ファーマシューティカルズ， インコーポレイティド 乱用耐性のオピオイド投薬形態
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
AU2002314968B2 (en) 2001-06-08 2006-12-07 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
WO2003002100A1 (en) 2001-06-26 2003-01-09 Farrell John J Tamper-proof narcotic delivery system
DK1404331T3 (da) * 2001-07-06 2008-01-28 Penwest Pharmaceuticals Co Sustained release-formuleringer af oxymorphon
MXPA04001208A (es) 2001-08-06 2004-07-08 Euro Celtique Sa Composiciones y metodos para evitar el abuso de los opioides.
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
CA2455420A1 (en) 2001-08-06 2003-02-20 Euro-Celtique, S.A. Compositions and methods to prevent abuse of opioids
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
AU2002321879A1 (en) 2001-08-06 2003-03-03 Thomas Gruber Pharmaceutical formulation containing dye
US20030069318A1 (en) * 2001-08-21 2003-04-10 Wenbin Dang Salts of analgesic substances in oil, and methods of making and using the same
US6691698B2 (en) 2001-09-14 2004-02-17 Fmc Technologies Inc. Cooking oven having curved heat exchanger
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2003024430A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1429735A2 (de) 2001-09-26 2004-06-23 Klaus-Jürgen Steffens Verfahren und vorrichtung zur herstellung von granulaten umfassend mindestens einen pharmazeutischen wirkstoff
US6982094B2 (en) 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
DE60237294D1 (de) 2001-09-28 2010-09-23 Mcneil Ppc Inc Pharmazeutische zusammensetzung auf fondantbasis
US20030229158A1 (en) 2001-09-28 2003-12-11 Chen Jen Chi Polymer composition and dosage forms comprising the same
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
FR2833838B1 (fr) 2001-12-21 2005-09-16 Ellipse Pharmaceuticals Procede de fabrication d'un comprime incluant un analgesique de type morphinique et comprime obtenu
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
AU2003211146B2 (en) 2002-02-21 2007-07-19 Valeant International (Barbados) Srl Controlled release dosage forms
GB0204772D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms
DE10217232B4 (de) * 2002-04-18 2004-08-19 Ticona Gmbh Verfahren zur Herstellung gefüllter Granulate aus Polyethylenen hohen bzw. ultrahohen Molekulargewichts
CA2483655A1 (en) * 2002-04-29 2003-11-13 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US20060073102A1 (en) 2002-05-13 2006-04-06 Huaihung Kao D Abuse-resistant opioid solid dosage form
AU2003234621A1 (en) * 2002-05-17 2003-12-02 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
JP2005528423A (ja) 2002-05-31 2005-09-22 アルザ・コーポレーシヨン オキシコドンの変動性投薬用量の浸透圧的送達のための剤形および組成物
DE10250083A1 (de) 2002-06-17 2003-12-24 Gruenenthal Gmbh Gegen Missbrauch gesicherte Darreichungsform
US7776314B2 (en) * 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
JP4694207B2 (ja) * 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
US20040011806A1 (en) * 2002-07-17 2004-01-22 Luciano Packaging Technologies, Inc. Tablet filler device with star wheel
AU2003261223A1 (en) 2002-07-25 2004-02-16 Pharmacia Corporation Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former
EP1537118A1 (en) 2002-08-15 2005-06-08 Noramco, Inc. Oxycodone-hydrochloride polymorhs
US7815924B2 (en) 2002-09-20 2010-10-19 Fmc Corporation Cosmetic composition containing microcrystalline cellulose
EP1551402A4 (en) 2002-09-23 2009-05-27 Verion Inc PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE
CA2500311A1 (en) * 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Modified release dosage forms
DE10250088A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10250087A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US20040110781A1 (en) 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
AU2004232370B2 (en) 2003-04-21 2009-12-10 Euro-Celtique S.A. Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
US8778382B2 (en) 2003-04-30 2014-07-15 Purdue Pharma L.P. Tamper resistant transdermal dosage form
JP2007516220A (ja) 2003-05-06 2007-06-21 ビーピーエスアイ ホールディングス，インコーポレーテッド アクリルポリマー接着剤を含有する熱成形組成物の製造方法、医薬製剤および該製剤の製造方法
US20040241234A1 (en) 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050031655A1 (en) 2003-08-04 2005-02-10 Schering Plough Healthcare Products, Inc. Emulsion composition
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004020220A1 (de) 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
BR122018068298B8 (pt) 2003-08-06 2021-07-27 Gruenenthal Gmbh processo para a produção de um comprimido seguro contra abuso termo-moldado por extrusão sem descoramento
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
JP5670609B2 (ja) * 2003-09-26 2015-02-18 アルザ・コーポレーシヨン 有効成分の制御送達のためのｏｒｏｓプッシュ−スティック
US20050074493A1 (en) 2003-10-03 2005-04-07 Mehta Atul M. Extended release formulations of opioids and method of use thereof
CA2546691A1 (en) 2003-10-29 2005-05-12 Alza Corporation Once-a-day, oral, controlled-release, oxycodone dosage forms
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
AU2004314224A1 (en) 2004-01-23 2005-08-04 Antoine Sakellarides Shock absorbing system for rowing boat oarlock
WO2005079752A2 (en) 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
TWI365880B (en) * 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
JP5064209B2 (ja) * 2004-04-22 2012-10-31 グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 乱用防止固体剤形を製造する方法
JP2006002884A (ja) * 2004-06-18 2006-01-05 Mitsubishi Plastics Ind Ltd 連結具
JP2006002886A (ja) * 2004-06-18 2006-01-05 Noriatsu Kojima 排水管
US20070257449A1 (en) * 2004-06-22 2007-11-08 Alain Pelchat Sealing molding for a Motor Vehicle
PL1765298T3 (pl) 2004-07-01 2013-01-31 Gruenenthal Gmbh Sposób wytwarzania stałej postaci dawkowania, która jest zabezpieczona przez nadużywaniem, wykorzystujący wytłaczarkę z przekładnią planetarną
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006002886A1 (de) 2004-07-01 2006-01-12 Grünenthal GmbH Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
WO2006002884A1 (de) * 2004-07-01 2006-01-12 Grünenthal GmbH Gegen missbrauch gesicherte, orale darreichtungsform
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
EP2319499A1 (en) 2005-01-28 2011-05-11 Euro-Celtique S.A. Alcohol resistant dosage forms
US20080274183A1 (en) 2005-02-04 2008-11-06 Phillip Michael Cook Thermoplastic articles containing a medicament
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
AU2006269225B2 (en) 2005-07-07 2011-10-06 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20070212414A1 (en) 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US7778314B2 (en) 2006-05-04 2010-08-17 Texas Instruments Incorporated Apparatus for and method of far-end crosstalk (FEXT) detection and estimation
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP2121699B1 (en) 2006-12-04 2012-09-19 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
AR064875A1 (es) 2007-01-12 2009-04-29 Wyeth Corp Composiciones de tableta en tableta
WO2008086804A2 (en) 2007-01-16 2008-07-24 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
CA2720108C (en) 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8671872B2 (en) 2009-02-16 2014-03-18 Thomas Engineering Inc. Production coater with exchangeable drums
AU2010275753B2 (en) * 2009-07-22 2014-08-21 Grünenthal GmbH Hot-melt extruded controlled release dosage form
US9492492B2 (en) * 2010-12-17 2016-11-15 Johnson & Johnson Consumer Inc. Compositions comprising Lilium martagon extracts and uses thereof
EP2826469A1 (en) * 2010-12-22 2015-01-21 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9846413B2 (en) * 2011-09-08 2017-12-19 Fire Avert, Llc. Safety shut-off device and method of use
US10764498B2 (en) * 2017-03-22 2020-09-01 Canon Kabushiki Kaisha Image processing apparatus, method of controlling the same, and storage medium
US10764499B2 (en) * 2017-06-16 2020-09-01 Microsoft Technology Licensing, Llc Motion blur detection

Also Published As

Publication number Publication date
KR101455914B1 (ko) 2014-11-03
US9492393B2 (en) 2016-11-15
SI1897545T1 (sl) 2010-01-29
CN105267170B (zh) 2019-01-01
EP2343071A1 (en) 2011-07-13
US9770417B2 (en) 2017-09-26
US20170128373A1 (en) 2017-05-11
SI2292230T1 (sl) 2012-09-28
PE20191048A1 (es) 2019-08-06
US9486412B2 (en) 2016-11-08
IL217791A0 (en) 2012-03-29
PL2292229T3 (pl) 2012-10-31
JP5069300B2 (ja) 2012-11-07
US8846086B2 (en) 2014-09-30
EA201171403A1 (ru) 2012-05-30
IL217791A (en) 2015-09-24
ES2417334T3 (es) 2013-08-07
DK2311459T3 (da) 2012-09-10
PL2343071T3 (pl) 2013-12-31
IL217789A0 (en) 2012-03-29
DK1897545T3 (da) 2010-02-08
CN102657630A (zh) 2012-09-12
AT11571U1 (de) 2011-01-15
EP2292230B1 (en) 2012-05-23
PT2343071E (pt) 2013-05-29
US20190000767A1 (en) 2019-01-03
CA2707204A1 (en) 2008-02-28
HRP20120613T1 (hr) 2012-08-31
EP2399579A1 (en) 2011-12-28
EP2070538B1 (en) 2010-12-01
EP2292229A1 (en) 2011-03-09
US20210169810A1 (en) 2021-06-10
US20180153814A1 (en) 2018-06-07
US20170319497A1 (en) 2017-11-09
HK1165318A1 (en) 2012-10-05
JP2012136543A (ja) 2012-07-19
CY1111896T1 (el) 2015-11-04
EP2080514A1 (en) 2009-07-22
HRP20130444T1 (en) 2013-06-30
US11964056B1 (en) 2024-04-23
PT1897545E (pt) 2009-12-16
KR20170118249A (ko) 2017-10-24
JP2015044834A (ja) 2015-03-12
EA023807B1 (ru) 2016-07-29
EP2384754A1 (en) 2011-11-09
KR101514388B1 (ko) 2015-04-23
US20150265601A1 (en) 2015-09-24
US8911719B2 (en) 2014-12-16
CY1113231T1 (el) 2016-04-13
US20170128369A1 (en) 2017-05-11
EP2082742B1 (en) 2010-12-01
US20170128371A1 (en) 2017-05-11
KR20120105566A (ko) 2012-09-25
SI2082742T1 (sl) 2011-03-31
SI2080514T1 (sl) 2011-05-31
US20170319496A1 (en) 2017-11-09
WO2008023261A1 (en) 2008-02-28
ES2411695T3 (es) 2013-07-08
DE602007012747D1 (de) 2011-04-07
AR103463A2 (es) 2017-05-10
HRP20130434T1 (en) 2013-06-30
US20240226019A1 (en) 2024-07-11
ME01482B (me) 2014-04-20
US20150335584A1 (en) 2015-11-26
SI2399580T1 (sl) 2013-07-31
ES2358066T3 (es) 2011-05-05
HK1154491A1 (en) 2012-04-27
US20130260015A1 (en) 2013-10-03
US9770416B2 (en) 2017-09-26
IL241121A0 (en) 2015-11-30
CY1113141T1 (el) 2016-04-13
IL217794A (en) 2015-09-24
US20170128440A1 (en) 2017-05-11
US20140030327A1 (en) 2014-01-30
DK2080514T3 (da) 2011-05-16
US20170319493A1 (en) 2017-11-09
KR101496510B1 (ko) 2015-03-03
US20170128370A1 (en) 2017-05-11
US9492391B2 (en) 2016-11-15
US20150028512A1 (en) 2015-01-29
JP5642736B2 (ja) 2014-12-17
ES2361721T3 (es) 2011-06-21
PT2384754E (pt) 2013-05-24
CN102688241A (zh) 2012-09-26
PE20150340A1 (es) 2015-02-28
US9486413B2 (en) 2016-11-08
US9775811B2 (en) 2017-10-03
HRP20130433T1 (en) 2013-06-30
HK1133192A1 (en) 2010-03-19
BRPI0714539B1 (pt) 2020-11-24
US20150335585A1 (en) 2015-11-26
SI2399579T1 (sl) 2013-07-31
EP2070538A1 (en) 2009-06-17
CA2661573C (en) 2010-10-26
CN102688241B (zh) 2017-04-12
US20170065527A1 (en) 2017-03-09
MX2009002023A (es) 2009-03-05
PT2080514E (pt) 2011-05-24
US10076498B2 (en) 2018-09-18
US20170319491A1 (en) 2017-11-09
US20150335580A1 (en) 2015-11-26
JP6286491B2 (ja) 2018-02-28
CY1113220T1 (el) 2016-04-13
US20130251799A1 (en) 2013-09-26
US9492390B2 (en) 2016-11-15
EA201300465A1 (ru) 2013-08-30
SI2384754T1 (sl) 2013-07-31
BRPI0714539A2 (pt) 2014-02-25
PT2292230E (pt) 2012-08-28
AU2007287341B2 (en) 2011-08-25
PT2399579E (pt) 2013-06-24
ATE444070T1 (de) 2009-10-15
DK2070538T3 (da) 2011-03-21
US9101661B2 (en) 2015-08-11
HRP20110375T1 (hr) 2011-06-30
BRPI0714539B8 (pt) 2021-05-25
US9084816B2 (en) 2015-07-21
CA2661573A1 (en) 2008-02-28
US8808741B2 (en) 2014-08-19
KR20120105565A (ko) 2012-09-25
ES2390419T3 (es) 2012-11-12
CN103861111B (zh) 2017-04-12
CR20140340A (es) 2014-10-16
EP2384754B1 (en) 2013-03-20
KR101787605B1 (ko) 2017-10-19
JP2012167102A (ja) 2012-09-06
RS51591B (en) 2011-08-31
JP5373133B2 (ja) 2013-12-18
DE602007002596D1 (de) 2009-11-12
DE602007010974D1 (de) 2011-01-13
IL217788A0 (en) 2012-03-29
JP2012236835A (ja) 2012-12-06
CR10691A (es) 2009-06-05
US20170319490A1 (en) 2017-11-09
US9095615B2 (en) 2015-08-04
JO3323B1 (ar) 2019-03-13
US11938225B2 (en) 2024-03-26
EP2343071B1 (en) 2013-03-20
US8815289B2 (en) 2014-08-26
CN101583360A (zh) 2009-11-18
PL2399580T3 (pl) 2013-12-31
US20170128375A1 (en) 2017-05-11
EP2399580B1 (en) 2013-04-03
EA018311B1 (ru) 2013-07-30
DK2082742T3 (da) 2011-03-21
PL2292230T3 (pl) 2012-10-31
HK1154788A1 (en) 2012-05-04
US20210000747A1 (en) 2021-01-07
ME01064B (me) 2012-10-20
CN102743355B (zh) 2014-12-24
US9775808B2 (en) 2017-10-03
EA200900343A1 (ru) 2009-08-28
RS51162B (sr) 2010-10-31
US11304908B2 (en) 2022-04-19
US20150265599A1 (en) 2015-09-24
CN105213345B (zh) 2019-04-19
CL2017000669A1 (es) 2017-11-10
RS52401B (en) 2013-02-28
US20130259939A1 (en) 2013-10-03
US20140024669A1 (en) 2014-01-23
US20170128372A1 (en) 2017-05-11
AP2009004770A0 (en) 2009-02-28
BR122016004010B8 (pt) 2021-05-25
CY1111897T1 (el) 2015-11-04
ATE499101T1 (de) 2011-03-15
US20130251796A1 (en) 2013-09-26
US8834925B2 (en) 2014-09-16
PL2311459T3 (pl) 2012-12-31
US20180153815A1 (en) 2018-06-07
ES2388591T3 (es) 2012-10-16
ME01550B (me) 2014-04-20
US20170354607A1 (en) 2017-12-14
US11298322B2 (en) 2022-04-12
DOP2009000026A (es) 2009-07-15
US9775810B2 (en) 2017-10-03
US11904055B2 (en) 2024-02-20
EP2292229B1 (en) 2012-05-23
KR20090045381A (ko) 2009-05-07
US20130251802A1 (en) 2013-09-26
US8894987B2 (en) 2014-11-25
EP2311459B1 (en) 2012-06-27
US9095614B2 (en) 2015-08-04
US20170319488A1 (en) 2017-11-09
ATE489953T1 (de) 2010-12-15
CL2007002485A1 (es) 2008-01-25
ES2388615T3 (es) 2012-10-17
ES2411696T3 (es) 2013-07-08
US20130251801A1 (en) 2013-09-26
CN103861111A (zh) 2014-06-18
CN105213345A (zh) 2016-01-06
KR20110119847A (ko) 2011-11-02
HK1246175A1 (zh) 2018-09-07
HRP20120641T1 (hr) 2012-08-31
US20240115507A1 (en) 2024-04-11
PT2311459E (pt) 2012-09-26
DK2292230T3 (da) 2012-08-20
NZ574447A (en) 2012-04-27
HRP20110147T1 (hr) 2011-04-30
RS52798B (en) 2013-10-31
PT2292229E (pt) 2012-08-28
JP5980881B2 (ja) 2016-08-31
US20180369150A1 (en) 2018-12-27
US9775809B2 (en) 2017-10-03
CY1110573T1 (el) 2015-04-29
US20170348241A1 (en) 2017-12-07
US20130259938A1 (en) 2013-10-03
EP2399579B9 (en) 2013-07-24
ME01339B (me) 2013-12-20
AR109797A2 (es) 2019-01-23
EP1897545B1 (en) 2009-09-30
PL2082742T3 (pl) 2011-05-31
DK2343071T3 (da) 2013-05-13
BR122016004010B1 (pt) 2020-11-24
ES2417335T3 (es) 2013-08-07
IL197214A0 (en) 2009-12-24
US20130251800A1 (en) 2013-09-26
MY153092A (en) 2014-12-31
AR062511A1 (es) 2008-11-12
US20210000749A1 (en) 2021-01-07
KR101649838B1 (ko) 2016-08-19
CA2707204C (en) 2015-06-23
PE20091184A1 (es) 2009-08-03
CN102657630B (zh) 2014-10-01
EP2399579B1 (en) 2013-04-03
HK1165316A1 (en) 2012-10-05
US20090081290A1 (en) 2009-03-26
PT2070538E (pt) 2011-03-02
PL2070538T3 (pl) 2011-05-31
IN2015DN01813A (el) 2015-07-10
US9545380B2 (en) 2017-01-17
DE602007010963D1 (de) 2011-01-13
PL2399579T3 (pl) 2013-12-31
PL2080514T3 (pl) 2011-09-30
ME01187B (me) 2011-10-31
US9492392B2 (en) 2016-11-15
IL217792A (en) 2015-09-24
UA104745C2 (ru) 2014-03-11
CN102743355A (zh) 2012-10-24
IL197214A (en) 2015-09-24
CN107412179B (zh) 2020-09-04
RS52793B (en) 2013-10-31
PL1897545T3 (pl) 2010-02-26
CN107412179A (zh) 2017-12-01
US20170319492A1 (en) 2017-11-09
DOP2011000255A (es) 2011-10-15
ES2357376T3 (es) 2011-04-25
ZA200900755B (en) 2009-12-30
RS52463B (en) 2013-02-28
US20140031381A1 (en) 2014-01-30
DK2384754T3 (da) 2013-05-06
RS52779B (en) 2013-10-31
ME01255B (me) 2013-06-20
RS51664B (en) 2011-10-31
IL217787A0 (en) 2012-03-29
MX360849B (es) 2018-11-20
US20130251797A1 (en) 2013-09-26
US11304909B2 (en) 2022-04-19
US20170128374A1 (en) 2017-05-11
EP2399580A1 (en) 2011-12-28
HK1138498A1 (en) 2010-08-27
NZ608651A (en) 2014-07-25
IL217790A0 (en) 2012-03-29
MY146650A (en) 2012-09-14
US8894988B2 (en) 2014-11-25
TWI341213B (en) 2011-05-01
GT200900023A (es) 2010-11-05
CO6160317A2 (es) 2010-05-20
SA07280459B1 (ar) 2011-07-20
SI2070538T1 (sl) 2011-03-31
CN101583360B (zh) 2014-02-26
US10076499B2 (en) 2018-09-18
KR101568100B1 (ko) 2015-11-12
PT2082742E (pt) 2011-03-02
US20150037412A1 (en) 2015-02-05
US8821929B2 (en) 2014-09-02
IL241122A0 (en) 2015-11-30
US20170319489A1 (en) 2017-11-09
US20230310326A1 (en) 2023-10-05
US20130259940A1 (en) 2013-10-03
HK1132189A1 (en) 2010-02-19
JP2010501543A (ja) 2010-01-21
DK2399579T3 (da) 2013-06-17
US20150265600A1 (en) 2015-09-24
SI2311459T1 (sl) 2012-10-30
HK1118225A1 (en) 2009-02-06
US20130251798A1 (en) 2013-09-26
PL2384754T3 (pl) 2013-12-31
DK2399580T3 (da) 2013-06-24
US20230134700A1 (en) 2023-05-04
HK1165317A1 (en) 2012-10-05
ES2334466T3 (es) 2010-03-10
CN105267170A (zh) 2016-01-27
IL217792A0 (en) 2012-03-29
MA30766B1 (fr) 2009-10-01
KR20160099738A (ko) 2016-08-22
IL217794A0 (en) 2012-03-29
TW200824722A (en) 2008-06-16
IL241121A (en) 2017-09-28
PT2399580E (pt) 2013-07-05
US9763886B2 (en) 2017-09-19
HRP20130539T1 (en) 2013-07-31
JO2858B1 (en) 2015-03-15
HK1156845A1 (en) 2012-06-22
EP1897545A1 (en) 2008-03-12
CY1111887T1 (el) 2015-11-04
JP2016222698A (ja) 2016-12-28
US20170246116A1 (en) 2017-08-31
CL2014001029A1 (es) 2014-09-12
RS52813B (en) 2013-10-31
PE20140854A1 (es) 2014-07-19
RS51678B (en) 2011-10-31
KR101205579B1 (ko) 2012-11-28
KR20150082669A (ko) 2015-07-15
US20150037411A1 (en) 2015-02-05
KR20140049085A (ko) 2014-04-24
CN102688213A (zh) 2012-09-26
HRP20090688T1 (hr) 2010-02-28
US20170319498A1 (en) 2017-11-09
US20170319494A1 (en) 2017-11-09
AU2007287341A1 (en) 2008-02-28
US20170319495A1 (en) 2017-11-09
MY161079A (en) 2017-04-14
NZ597760A (en) 2013-04-26
SI2343071T1 (sl) 2013-07-31
ME01580B (me) 2014-09-20
EP2082742A1 (en) 2009-07-29
TN2009000059A1 (fr) 2010-08-19
US20150335583A1 (en) 2015-11-26
US9492389B2 (en) 2016-11-15
US20150037413A1 (en) 2015-02-05
IL241122B (en) 2019-05-30
EP2080514B1 (en) 2011-02-23
US20210000748A1 (en) 2021-01-07
EP2292230A1 (en) 2011-03-09
US11826472B2 (en) 2023-11-28
HK1154789A1 (en) 2012-05-04
ATE489954T1 (de) 2010-12-15
RS52402B (en) 2013-02-28
EP2311459A1 (en) 2011-04-20
DE202007011825U1 (de) 2008-04-30
US20230270684A1 (en) 2023-08-31
AR109796A2 (es) 2019-01-23
US20170348240A1 (en) 2017-12-07
SI2292229T1 (en) 2012-09-28
US9763933B2 (en) 2017-09-19
EA031873B1 (ru) 2019-03-29
PE20080765A1 (es) 2008-06-13
DK2292229T3 (da) 2012-08-13
HRP20120670T1 (hr) 2012-09-30
HRP20110130T1 (hr) 2011-03-31
JP2012229249A (ja) 2012-11-22
JP2012229250A (ja) 2012-11-22
US20150335582A1 (en) 2015-11-26
US9775812B2 (en) 2017-10-03
UA96306C2 (ru) 2011-10-25

Similar Documents

Publication Publication Date Title
GT200900023BA (es) Formas de dosificación farmacéutica
MA32934B1 (fr) Combinaisons inhibitrices hsp90
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX342643B (es) Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA200802324A1 (ru) Новая форма введения рацекадотрила
CL2015000110A1 (es) Metodo de prevencion o tratamiento de una respuesta farmacodinamica adversa inducida por opioides; unidad de dosis farmaceutica que comprende buprenorfina y otro opioide; kit farmaceutico. (divisional de la solicitud n°2790-2014).
CL2011002569A1 (es) Procedimiento de tratamiento o prevencion que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r.
EA201171414A1 (ru) Ингибиторы белков семейства iap
UY31662A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de elaboracion.
EA200970816A1 (ru) Новая лекарственная форма
GT200800208A (es) Composición farmacèutica que comprende la combinación de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia.
WO2007121356A3 (en) Method of treatment with predictably breakable pharmaceutical tablets
CY1114060T1 (el) Φαρμακευτικες μορφες δοσολογιας
MX2009012458A (es) Forma de dosificacion oral que permite una rapida absorcion de un farmaco.